Stephen Rocamboli, Director at Esperion Therapeutics, Inc. (ESPR), bought 8,111 shares at $1.50 ($12K) on 2023-05-10, disclosed to the SEC on 2023-05-11.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| TFFP | BUY | 2022-05-17 | $14K | — | Filing → |
| TFFP | SELL | 2021-03-17 | $674K | — | Filing → |
| TFFP | SELL | 2020-11-13 | $1.1M | — | Filing → |